Tirzepatide vs MOTS-c
Side-by-side comparison of Tirzepatide and MOTS-c: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
Tirzepatide
MOTS-c
Tirzepatide
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with a molecular weight of 4813.45 Da and CAS number 2023788-19-2. It is a 39-amino-acid…
Lowest listed price: $49.00 across 14 listings
Full Tirzepatide profileMOTS-c
MOTS-c (Mitochondrial ORF of the Twelve S rRNA type-c) is a 16-amino-acid mitochondrial-derived peptide — a member of a recently discovered class of small peptides encoded in mitochondrial DNA rather than nuclear DNA. It…
Lowest listed price: $44.99 across 9 listings
Full MOTS-c profileSide-by-side comparison
| Attribute | Tirzepatide | MOTS-c |
|---|---|---|
| Category | Metabolic & Weight Loss | Longevity & Cellular Health |
| Research Stage | FDA Approved | Preclinical |
| Mechanism of Action | Dual GLP-1 and GIP Receptor Agonism Tirzepatide simultaneously activates two incretin receptors: the GLP-1 receptor and the GIP receptor. While the GLP-1 receptor component provides the well-established effects of GLP-1 agonism (glucose-dependent insulin… | A New Class of Signaling Molecule MOTS-c belongs to the mitochondrial-derived peptides (MDPs) - a class of small peptides encoded within mitochondrial DNA open reading frames that were historically thought to encode only ribosomal RNAs. The known MDPs include:… |
| Half-Life | ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification | ~4–6 hours |
| Typical Dose Range | 2500 mcg (2.5 mg) starting dose, titrated every 4 weeks through 5000, 7500, 10000, 12500, to 15000 mcg (15 mg) maximum weekly dose | 5,000–10,000 mcg (5–10 mg) per injection |
| Dosing Frequency | Once weekly subcutaneous injection | 2-3 times per week |
| Administration | Subcutaneous (weekly) | Subcutaneous, Intramuscular |
| Side Effects | Mild to moderate nausea (especially at initiation), headache, fatigue, constipation or diarrhea, abdominal distension. Injection site reactions. Rare: hypoglycemia, increased heart rate, pancreatitis. | Reported Effects (limited human data) - Injection site reactions — Mild erythema, transient itching at SC injection site. Site rotation minimizes. Probably the single most reported issue. - Transient fatigue — Some users report mild fatigue in the first week… |
| Molecular Weight | 4813.5 Da | 2174 Da |
| Common Vial Sizes | 5mg, 10mg, 15mg | 5mg, 10mg |
Price History
3 data points- BM
- Half Nattys
- Ion Peptide
Price History
5 data points- OF
- BM
- Half Nattys
- Ion Peptide
- Disguised Alpha
- BHG Labs
Tirzepatide: potential benefits
- Mean body weight reduction of 22.5% at 72 weeks - highest of any anti-obesity medication (PMID: 35658024)
- 36.2% of participants achieved greater than or equal to 25% body weight loss (PMID: 35658024)
- Significant HbA1c reduction in type 2 diabetes (up to 2.4% at 40 weeks in the SURPASS-5 add-on-to-insulin trial) (PMID: 35133415)
- Potentially superior lean mass preservation versus GLP-1-only agents due to GIP component
- Dual incretin mechanism providing complementary metabolic benefits
- Improved lipid profiles including triglycerides, LDL cholesterol, and HDL cholesterol
- Reduction in waist circumference and markers of visceral adiposity (PMID: 37840095)
MOTS-c: potential benefits
- Insulin sensitivity
- Exercise mimicry
- Metabolic health
- Anti-aging
- Fat oxidation
- Longevity
Frequently asked
What's the difference between Tirzepatide and MOTS-c?
Tirzepatide is a metabolic & weight loss that dual glp-1 and gip receptor agonism tirzepatide simultaneously activates two incretin receptors: the glp-1 receptor and the gip receptor. while the glp-1 receptor component…. MOTS-c is a longevity & cellular health that a new class of signaling molecule mots-c belongs to the mitochondrial-derived peptides (mdps) - a class of small peptides encoded within mitochondrial dna open reading frames that…. The two differ in mechanism, half-life (~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification vs ~4–6 hours), and typical dose range.
Which has the longer half-life, Tirzepatide or MOTS-c?
Tirzepatide has a half-life of ~5 days (approximately 120 hours), enabled by C20 fatty diacid albumin-binding modification. MOTS-c has a half-life of ~4–6 hours. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Which is cheaper, Tirzepatide or MOTS-c?
Lowest listed price on BodyHackGuide: Tirzepatide from $49.00, MOTS-c from $44.99. Prices are pulled from the vendor listings tracked on BHG and change frequently. See the compare tables on each compound page for the current set of offers.
Can you stack Tirzepatide and MOTS-c?
Stacking depends on mechanism overlap, safety profile, and goals. Tirzepatide and MOTS-c should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy Tirzepatide or MOTS-c
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. We earn an affiliate commission on some outbound clicks, and every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.